City
Epaper

New PharmEasy funding round 'sudden death' for founders: Ashneer Grover

By IANS | Updated: July 6, 2023 12:55 IST

New Delhi, July 6 Former BharatPe Co-founder Ashneer Grover on Thursday claimed that the new funding round by ...

Open in App

New Delhi, July 6 Former BharatPe Co-founder Ashneer Grover on Thursday claimed that the new funding round by the beleaguered unicorn PharmEasy is not a “down round" but actually the end and will bring "sudden death" for the company's founders owing to the anti-dilutive clause.

According to an earlier TechCrunch report citing sources, PharmEasy, which was once valued at $5 billion, plans to raise nearly $300 million at "a 90 per cent markdown from the previous valuation". PharmEasy will see its valuation nosedive to about $500-$600 million.

Reacting to the report, Grover tweeted: "Down Round + Anti-Dilutive Clause = Sudden Death (Jhatka) for the Founders!"

He said that if this news about PharmEasy is correct, it's not a down round but the end.

Explaining his argument, Grover said that since the anti-dilutive clause will kick in, it means that "VC investors who invested in PharmEasy at more than Rs 5/share ever will get more shares so their holding cost comes to Rs 5/share".

"Simply even last round VC investors who invested at Rs 55/ share will get 10x more shares for free so their holding comes to Rs 5/share. Everyone but the founders and Employees," he posted.

According to Grover, founders along with ESOP holding will become 0.001 per cent or some similar fraction at the company.

"Debt taken in 2021 will turn out to be the most expensive capital raised by founders ever," he further said.

Multiple reports on Wednesday said that online pharmacy startup PharmEasy which, according to multiple reports, is in deep crisis amid sharp valuation cut as it seeks new funding.

The reports claimed that PharmEasy is raising fresh funds to pay its lender Goldman Sachs from which it borrowed nearly $285 million last year as it took a majority stake in diagnostics solution provider Thyrocare for over $600 million.

Money Control first reported that Manipal Group has expressed interest in investing approximately Rs 1,000 crore for an 18 per cent stake in API Holdings, the owner of online pharmacy PharmEasy and promoter of Thyrocare.

"Furthermore, existing investors of API Holdings are expected to contribute approximately Rs 1,500 crore in a funding round led by Manipal Group," said the report.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Goldman SachsEsopGoldman sachs -lrb-india-rrb- securities private limitedGoldman sachs services in indiaAshneer groverEsop subscription servicesIim bangalore goldman sachsGoldman sachs 2021Goldman sachs asset management private creditGoldman sachs group inc
Open in App

Related Stories

EntertainmentAshneer Grover Breaks Silence After Salman Khan's Confrontation on Bigg Boss 18 (See Post)

EntertainmentBigg Boss 18: Salman Khan Mocks Ashneer Grover's ‘Doglapan’ on Weekend Ka War, Video Goes Viral

EntertainmentBigg Boss 18 Promo: Dolly Chaiwala, Ashneer Grover, and Khushi Join Salman Khan on Stage (Watch Video)

BusinessFormer Shark Tank Judge Ashneer Grover Threatens Legal Action Over Comedian's Roast

BusinessAshneer Grover's New Company: Former Shark Tank Judge to Launch his New Firm ZeroPe App

National Realted Stories

NationalKerala: Pinarayi Vijayan’s daughter responds to ‘false’ news

National15th Rozgar Mela: Appointees celebrate nationwide as PM Modi distributes over 51,000 appointment letters

NationalIndia’s human-centric approach to tech and AI align with PM Modi’s vision: Minister

NationalRozgar Mela 2025: Work honestly, diligently to make India developed, self-reliant nation, say Ministers

NationalNortheastern states should effectively utilise hydro-power potential: Manohar Lal